Orchid BioSciences, Inc ORCH Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Orchid BioSciences, Inc ORCH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rich987 who wrote (76)	2/10/2004 8:20:19 PM
From: rich987	Read Replies (1) of 94

after hours up close to 2.30 from 2.09 with over 1mm shares 02/10/2004 Dow Jones News Services (Copyright © 2004 Dow Jones & Company, Inc.) NEW YORK (Dow Jones)--Orchid BioSciences Inc. (ORCH) will focus its core capabilities on the service of DNA testing where the market is strong and opportunities are great, said Paul Kelly, the company's chief executive. The company, Kelly said on CNBC Tuesday, has strong market leadership, which is "about to explode," especially in the field of forensics. The company is a leader in testing sheep for a disease similar to mad cow. Orchid on Tuesday said it still expects 2003 revenue of about $50 million, and sees a 20% increase in 2004 revenue over 2003. The company also said it's seeking shareholder approval to implement a reverse stock split ranging from 1-for-3 shares to 1-for-7. A special meeting will be held Feb. 27 to consider this proposal. From a 52-week low of 33 cents in March, Orchid shares climbed to a 52-week high of $2.74 on Jan. 5. The shares closed Tuesday at $2.09. - By Adam L. Freeman, Dow Jones Newswires; 201-938-5023; adam.freeman@dowjones.com (END) Dow Jones Newswires 02-10-04 1814ET

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next